Vizgen
Vizgen launched MERFISH 2.0 chemistry and enhanced OmniVue panels with antibody-drug-conjugate (ADC) biomarker capability in 2026, alongside a spatial multi-omics roadmap unveiled at AGBT 2026 and new volumetric tissue-mapping capability presented at the Human Cell Atlas 2026 meeting.
- Country
- United States
merfish-platform
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Spatial epigenomics | bioinformatics-omics | Medium | → |
| Spatial transcriptomics & spatial multi-omics | bioinformatics-omics | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.